ClinicalTrials.gg
CompletedNCT04053634RESOLUTEUpdated Nov 20, 2026Results posted

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

A Phase 3 interventional study of Benralizumab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 342 sites in 30 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
689
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
49th of 194
689 · median 137
Started
2019
with 5 others
Phase 3
76 of 284
4 open now
Registered
225th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 49th largest by enrollment of the 194 interventional ones that give a count, is one of 6 that started in 2019, is one of 76 in phase 3, and was the 225th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).

Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.

The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • benralizumab
  • Fasenra
  • ICS
  • inhaled corticosteroids
  • exacerbations
  • Lung Disease
  • LABA/LAMA
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of
  2. Age 40 to 85 years
  3. Male and/or female.
  4. Current or former smoker with a tobacco history of ≥10 pack-years.
  5. History of moderate to very severe with a post-bronchodilator /FVC\<0.70 and FEV1 ≤65% of predicted normal value.
  6. Documented history of 2 or more COPD exacerbations that required treatment with systemic and/or hospitalization within 52 weeks prior to enrollment.

    1. Exacerbations treated with antibiotics alone are excluded unless accompanied by treatment with systemic corticosteroids and/or hospitalization.
    2. Hospitalization is defined as an inpatient admission ≥24 hours
    3. Previous exacerbations should be confirmed to have occurred while on stable triple therapy for COPD.
    4. At least one qualifying COPD exacerbation should occur while on stable uninterrupted triple therapy prior to enrolment.
  7. Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for ≥3 months immediately prior to enrollment.

    1. Treatment with at least double inhaled therapy containing ICS (e.g. ICS/LABA or ICS/LAMA) for the remaining of 52 weeks prior to enrolment. Use of LABA/LAMA is allowed if ICS cannot be tolerated.
    2. ICS in a dose approved for COPD or equivalent to ≥250 mcg of fluticasone propionate daily.
    3. Total cumulative duration of not being on double or triple background therapy must not exceed 2 months.
    4. Stable therapy/doses for the last 3 months prior to randomization.
  8. Blood eosinophil count ≥300/μL at screening and documented historical eosinophil count of ≥150/μL within 52 weeks of enrollment (or repeated testing during run-in).
  9. CAT total score ≥15 at Visit 1.
  10. Negative pregnancy test for females of (WOCBP) at Visit 1.
  11. Women of childbearing potential (WOCBP) must agree to use a highly effective method of from enrollment throughout the study and within 12 weeks after last dose of IP.

Women not of childbearing potential are defined as women who are either permanently sterilized or (confirmed by FSH test for women \<50 years).

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than
  2. Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
  3. Radiological findings of a respiratory disease other than COPD contributing to respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or findings of acute infection.
  4. Another pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
  5. Any unstable disorder that could affect patient safety, study findings or the patient's ability to complete the study.
  6. Any clinically significant abnormal findings in physical examination, vital signs, , laboratory tests could affect patient safety, study findings or the patient's ability to complete the study.
  7. Cor pulmonale and/or right ventricular failure.
  8. Long-term treatment with oxygen >4.0 L/min and/or oxyhemoglobin saturation \<89% while breathing supplemental oxygen.
  9. Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of CPAP for Sleep Apnea Syndrome is allowed.
  10. Known immunodeficiency disorder, including positive -1/2 testing.
  11. Active liver disease. Chronic stable and C (including positive HBsAg or antibody testing), or other stable chronic liver disease are acceptable.
  12. or AST ≥3 times the , confirmed by repeated testing during the run-in period.
  13. Helminth parasitic infection within 24 weeks prior to enrollment, not treated or failed to respond to standard of care therapy.
  14. Alcohol or drug abuse within the past year, which may compromise the study data.
  15. , current or within the past 5 years, except for adequately treated non invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms.
  16. Evidence of active tuberculosis, as judged by investigator. Patients with a recent (within 2 years) first-time or newly positive PPD or Quantiferon test need to complete an appropriate course of treatment before enrollment. Evaluation will be according to the local standard of care.
  17. Participation, or planned participation, in intensive COPD rehabilitation program (maintenance phase of a rehabilitation is allowed).
  18. History of surgical or endoscopic lung volume reduction within the 6 months prior to enrollment. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
  19. Scheduled major surgical procedure during the study. Minor elective procedures are allowed.
  20. History of anaphylaxis to any biologic therapy or vaccine.
  21. Receipt of blood products or immunoglobulins within 30 days prior to randomization.
  22. Receipt of marketed or biologic product within 4 months or 5 half-lives prior to randomization, whichever is longer. Exception: Patients on stable therapy for 3 months before randomization who intend to stay on treatment throughout the study with marketed biologic products that are not likely to interfere with the safety assessment and/or efficacy of benralizumab, for example, for the treatment of osteoporosis, migraine, pain, diabetes, obesity, ocular, cardiovascular, or metabolic diseases, can participate in the study.
  23. Receipt of 30 days prior to randomization.
  24. Chronic use of medication or expected need for chronic use during the study.
  25. Chronic use of antibiotics if duration of treatment is \<9 months prior to randomization. Chronic macrolide or other antibiotic therapy is allowed provided the patient has been on stable dose/regimen for ≥9 months prior to randomization and has had ≥2 COPD exacerbations while on stable therapy.
  26. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to enrollment.
  27. Receipt of benralizumab within 12 months prior to enrollment.
  28. Known history of allergy or reaction to any component of the IP formulation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
689 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

  • BiologicalPlacebo

    Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.

    Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: up to Week 56

  2. Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year

    Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: up to Week 56

Secondary outcomes

  1. Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year

    Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: Through study completion, a maximum of 296 weeks

  2. Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year

    Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: Through study completion, a maximum of 296 weeks

  3. Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year

    The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.

    Time frame: up to Week 56

  4. Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year

    The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.

    Time frame: up to Week 56

  5. Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year

    Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

    Time frame: up to Week 56

  6. Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year

    Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

    Time frame: up to Week 56

  7. Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year

    The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: Through study completion, a maximum of 296 weeks

  8. Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year

    The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

    Time frame: Through study completion, a maximum of 296 weeks

  9. Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year

    Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.

    Time frame: up to Week 56

  10. Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year

    Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.

    Time frame: up to Week 56

  11. Time From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year

    Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.

    Time frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.

  12. Time From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year

    Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.

    Time frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.

  13. Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.

    The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.

    Time frame: up to Week 56

  14. Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.

    The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.

    Time frame: up to Week 56

  15. Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.

    The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.

    Time frame: up to Week 56

  16. Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.

    The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.

    Time frame: up to Week 56

  17. All-cause and Respiratory-related Mortality of Participants With >=3 Exacerbations in the Previous Year.

    Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.

    Time frame: Through study completion, a maximum of 296 weeks.

  18. All-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.

    Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with a death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.

    Time frame: Through study completion, a maximum of 296 weeks.

07

Results

Posted Nov 20, 2026

Participant flow

A total of 689 participants were randomized, 13 of which were removed from analyses due to GCP non-compliance before study unblinding. The remaining 676 participants were randomized to either the benralizumab 100 mg arm (331 participants) or placebo arm (345 participants) of the double-blind treatment period.

Up to Week 56 (Primary Endpoint)
Participant flow — Up to Week 56 (Primary Endpoint)
MilestoneBenralizumab 100 mgPlacebo
Started331345
Completed289306
Not completed4239
Withdrew: Withdrawal by subject2119
Withdrew: Physician decision32
Withdrew: Adverse event35
Withdrew: Death138
Withdrew: Other reasons25
Through End of Treatment
Participant flow — Through End of Treatment
MilestoneBenralizumab 100 mgPlacebo
Started331345
Completed226218
Not completed105127
Withdrew: Withdrawal by subject5865
Withdrew: Physician decision54
Withdrew: Lost to follow-up11
Withdrew: Adverse event410
Withdrew: Death2833
Withdrew: Other reasons914

Outcome measures

PrimaryAnnualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.

Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
up to Week 56
Reported as:
Least squares mean · Exacerbations per participant-year
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.2.04 (1.69 to 2.46)2.46 (2.05 to 2.95)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.1172 · Rate ratio: 0.83 · 95% CI 0.66 to 1.05Comparison with placebo, a rate ratio \<1 favours Benralizumab.
PrimaryAnnualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year

Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring: Use of systemic corticosteroids for at least 3 days; and/or Use of antibiotics; and/or An inpatient hospitalization or death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
up to Week 56
Reported as:
Least squares mean · Exacerbations per participant-year
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year1.86 (1.58 to 2.20)2.05 (1.75 to 2.41)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.3367 · Rate ratio: 0.91 · 95% CI 0.74 to 1.11Comparison with placebo, a rate ratio \<1 favours Benralizumab.
SecondaryKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year

Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
Through study completion, a maximum of 296 weeks
Reported as:
Least squares mean · Exacerbations per participant-year
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year0.37 (0.28 to 0.49)0.39 (0.30 to 0.52)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.7644 · Rate ratio: 0.95 · 95% CI 0.67 to 1.35Comparison with placebo, a rate ratio \<1 favours Benralizumab.
SecondaryKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year

Severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
Through study completion, a maximum of 296 weeks
Reported as:
Least squares mean · Exacerbations per participant-year
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Key Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous Year0.37 (0.30 to 0.47)0.33 (0.26 to 0.42)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.4328 · Rate ratio: 1.13 · 95% CI 0.83 to 1.53Comparison with placebo, a rate ratio \<1 favours Benralizumab.
SecondaryKey Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year

The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.

Time frame:
up to Week 56
Reported as:
Mean · Score
Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year
ScoreBenralizumab 100 mgPlacebo
Total Score-7.06 ± 16.804-4.95 ± 16.915
Symptoms-7.16 ± 18.495-5.46 ± 16.822
Activity-8.34 ± 19.958-6.81 ± 18.663
Impacts-6.37 ± 20.335-3.75 ± 21.387
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.1686 · Difference in least squares means: -2.092 · 95% CI -5.072 to 0.889A difference of \<0 favours Benralizumab.
SecondaryKey Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year

The St. George's Respiratory Questionnaire (SGRQ) is a 50-item PRO instrument developed to measure the health status of patients with airway obstruction diseases. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment.

Time frame:
up to Week 56
Reported as:
Mean · Score
Key Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year
ScoreBenralizumab 100 mgPlacebo
Total Score-5.80 ± 16.185-3.89 ± 16.141
Symptoms-6.10 ± 18.104-4.97 ± 16.768
Activity-6.81 ± 19.381-4.96 ± 17.618
Impacts-5.20 ± 19.685-2.95 ± 20.592
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.1013 · Difference in least squares means: -2.014 · 95% CI -4.424 to 0.396A difference of \<0 favours Benralizumab.
SecondaryKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year

Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

Time frame:
up to Week 56
Reported as:
Mean · mL
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year
mLBenralizumab 100 mgPlacebo
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous Year10.8 ± 268.4817.3 ± 285.39
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.9729 · Mean difference (final values): 0.882 · 95% CI -50.081 to 51.844A difference \>0 favours Benralizumab.
SecondaryKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year

Pre-bronchodilator forced expiratory volume in 1 second (FEV1) is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

Time frame:
up to Week 56
Reported as:
Mean · mL
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year
mLBenralizumab 100 mgPlacebo
Key Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous Year18.3 ± 252.203.8 ± 259.60
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.2816 · Mean difference (final values): 21.965 · 95% CI -18.062 to 61.992A difference \>0 favours Benralizumab.
SecondaryAnnualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year

The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
Through study completion, a maximum of 296 weeks
Reported as:
Least squares mean · Exacerbations per participant-year
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous Year0.50 (0.39 to 0.64)0.60 (0.47 to 0.76)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.2589 · Rate ratio: 0.83 · 95% CI 0.61 to 1.14Comparison with placebo, a rate ratio \<1 favours Benralizumab.
SecondaryAnnualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year

The annualized rate of COPD exacerbations that are associated with an emergency room/emergency department (ER) or a hospitalization due to COPD through EOT are calculated similarly to the primary efficacy endpoint. The emergence room/emergence department (ER) and hospitalization due to COPD exacerbation are collected in COPDEX eCRF. Exacerbations per participant-year = 365.25\*Total Number of Exacerbations / Total time at risk within the treatment group (days)

Time frame:
Through study completion, a maximum of 296 weeks
Reported as:
Least squares mean · Exacerbations per participant-year
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year
Exacerbations per participant-yearBenralizumab 100 mgPlacebo
Annualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous Year0.48 (0.39 to 0.59)0.50 (0.41 to 0.61)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Negative binomial model · p = 0.7971 · Rate ratio: 0.97 · 95% CI 0.74 to 1.26Comparison with placebo, a rate ratio \<1 favours Benralizumab.
SecondaryTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year

Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.

Time frame:
up to Week 56
Reported as:
Median · Weeks
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year
WeeksBenralizumab 100 mgPlacebo
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous Year31.7 (24.1 to 40.4)26.1 (21.1 to 31.1)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Regression, Cox · p = 0.1331 · Hazard ratio (hr): 0.82 · 95% CI 0.66 to 1.03A hazard ratio of \< 1 favours Benralizumab.
SecondaryTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year

Time from randomization to the first moderate or severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first moderate or severe COPD exacerbation for patients who did experience a moderate or severe COPD exacerbation up to Week 56 were censored at Week 56, and for patients who discontinue or are lost-to-follow-up prior to Week 56, at the last time point after which an exacerbation could not be assessed.

Time frame:
up to Week 56
Reported as:
Median · Weeks
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year
WeeksBenralizumab 100 mgPlacebo
Time From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous Year33.0 (26.6 to 44.1)29.1 (25.6 to 33.0)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Regression, Cox · p = 0.2465 · Hazard ratio (hr): 0.87 · 95% CI 0.72 to 1.06A hazard ratio of \< 1 favours Benralizumab.
SecondaryTime From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year

Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.

Time frame:
From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
Reported as:
Median · Weeks
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year
WeeksBenralizumab 100 mgPlacebo
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous Year255.0 (157.1 to NA)194.6 (124.1 to NA)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Regression, Cox · p = 0.3566 · Hazard ratio (hr): 0.87 · 95% CI 0.63 to 1.19A hazard ratio of \< 1 favours Benralizumab.
SecondaryTime From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year

Time from randomization to the first severe COPD exacerbation = Start Date of first COPD exacerbation - Date of Randomization + 1. The time to first severe COPD exacerbation for patients who did experience a severe COPD exacerbation through EOT were censored at EOT, and for patients who discontinue or are lost-to-follow-up prior to EOT, at the last time point after which an exacerbation could not be assessed.

Time frame:
From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
Reported as:
Median · Weeks
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year
WeeksBenralizumab 100 mgPlacebo
Time From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous Year255.0 (190.0 to NA)NA (NA to NA)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Regression, Cox · p = 0.8201 · Hazard ratio (hr): 1.01 · 95% CI 0.77 to 1.32A hazard ratio of \< 1 favours Benralizumab.
SecondaryChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.

The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.

Time frame:
up to Week 56
Reported as:
Least squares mean · Score
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.
ScoreBenralizumab 100 mgPlacebo
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.-4.264 (-5.136 to -3.391)-2.391 (-3.260 to -1.523)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0030 · Mean difference (final values): -1.872 · 95% CI -3.104 to -0.641A difference \<0 favours Benralizumab.
SecondaryChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.

The CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential 6-point response scales, which are defined by contrasting objectives to capture the impact of COPD. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the sum of all item responses. Scores range from 0 to 40 with higher scores indicative of greater COPD impact on health status. A score cannot be calculated if \>2 responses are missing; when one or two items are missing, their scores can be set to the average of the non-missing item scores.

Time frame:
up to Week 56
Reported as:
Least squares mean · Score
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.
ScoreBenralizumab 100 mgPlacebo
Change From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.-4.021 (-4.761 to -3.281)-2.178 (-2.909 to -1.447)
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0005 · Mean difference (final values): -1.843 · 95% CI -2.883 to -0.802A difference \<0 favours Benralizumab.
SecondaryChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.

The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.

Time frame:
up to Week 56
Reported as:
Mean · Score
Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.
ScoreBenralizumab 100 mgPlacebo
Total Score-2.32 ± 6.602-1.49 ± 5.343
Breathlessness-0.76 ± 3.409-0.41 ± 2.839
Cough and Sputum-0.77 ± 1.836-0.60 ± 1.593
Chest Symptoms-0.78 ± 2.224-0.48 ± 1.850
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.1285 · Difference in least squares means: -0.795 · 95% CI -1.822 to 0.231Difference of \<0 favours Benralizumab.
SecondaryChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.

The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. The E-RS: COPD is a subset of items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0-17), cough and sputum (3 items; score range: 0-11) and chest symptoms (3 items; score range: 0-12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater severity.

Time frame:
up to Week 56
Reported as:
Mean · Score
Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.
ScoreBenralizumab 100 mgPlacebo
Total Score-1.95 ± 6.218-1.20 ± 5.245
Breathlessness-0.57 ± 3.196-0.29 ± 2.691
Cough and Sputum-0.67 ± 1.736-0.52 ± 1.576
Chest Symptoms-0.70 ± 2.071-0.39 ± 1.849
Statistical analysis
  • Benralizumab 100 mg vs Placebo · Mixed Models Analysis · p = 0.0931 · Difference in least squares means: -0.722 · 95% CI -1.565 to 0.121Difference of \<0 favours Benralizumab.
SecondaryAll-cause and Respiratory-related Mortality of Participants With >=3 Exacerbations in the Previous Year.

Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.

Time frame:
Through study completion, a maximum of 296 weeks.
Reported as:
Number · Death per 100 participant-year
All-cause and Respiratory-related Mortality of Participants With >=3 Exacerbations in the Previous Year.
Death per 100 participant-yearBenralizumab 100 mgPlacebo
All causes mortality3.005.05
Respiratory-related mortality1.802.32
SecondaryAll-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.

Respiratory related causes of death are summarised based on the SOC = Respiratory, thoracic and mediastinal disorders. Death per 100 participant-year is compared between treatment groups. Death per 100 participant-year is defined as number of subjects with a death divided by the total number of days at risk for death across all subjects in given treatment group, multiplied by 365.25 and then multiplied by 100. Total number of days at risk for death is defined as the duration from the first dose of IP to the date of death, or the duration from the first dose of IP to last visit for subjects without death.

Time frame:
Through study completion, a maximum of 296 weeks.
Reported as:
Number · Death per 100 participant-year
All-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.
Death per 100 participant-yearBenralizumab 100 mgPlacebo
All causes mortality3.724.62
Respiratory-related mortality2.132.31

Adverse events

Collected over AEs were collected from the first dose to the last date in study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 100 mg28/331 (8.5%)155/331 (46.8%)175/331 (52.9%)
Placebo34/345 (9.9%)186/345 (53.9%)193/345 (55.9%)
Most frequent serious events
Showing 10 of 217
Most frequent serious events
EventBenralizumab 100 mgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders87/331103/345
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations29/33121/345
PneumoniaInfections and infestations23/33121/345
Pneumonia bacterialInfections and infestations3/3319/345
Respiratory failureRespiratory, thoracic and mediastinal disorders4/3318/345
Acute respiratory failureRespiratory, thoracic and mediastinal disorders7/3312/345
InfluenzaInfections and infestations7/3316/345
Covid-19Infections and infestations6/3315/345
Covid-19 pneumoniaInfections and infestations3/3316/345
Acute myocardial infarctionCardiac disorders5/3314/345
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBenralizumab 100 mgPlacebo
NasopharyngitisInfections and infestations44/33159/345
Covid-19Infections and infestations48/33147/345
Upper respiratory tract infectionInfections and infestations31/33143/345
FallInjury, poisoning and procedural complications15/33135/345
Back painMusculoskeletal and connective tissue disorders26/33120/345
ConstipationGastrointestinal disorders26/33116/345
Urinary tract infectionInfections and infestations23/33126/345
PneumoniaInfections and infestations22/33125/345
HypertensionVascular disorders22/33118/345
HeadacheNervous system disorders20/33120/345

Baseline characteristics

All participants who were randomized and received any IP were included in the full analysis set.

Age, Categorical
Age, Categorical(Participants)Benralizumab 100 mgPlaceboTotal
<=18 years000
Between 18 and 65 years122136258
>=65 years209209418
Age, Continuous
Age, Continuous(Years)Benralizumab 100 mgPlaceboTotal
Mean67.0 ± 7.7266.8 ± 7.2866.9 ± 7.49
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 100 mgPlaceboTotal
Female101111212
Male230234464
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benralizumab 100 mgPlaceboTotal
Hispanic or Latino6162123
Not Hispanic or Latino270283553
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 100 mgPlaceboTotal
White244250494
Black or African American145
Asian6672138
Other201939
08

Study locations

342 sites
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Little Rock, Arkansas 72209, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Kissimmee, Florida 34741, United States
  • Research Site
    Kissimmee, Florida 34746, United States
  • Research Site
    Leesburg, Florida 34748, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Orlando, Florida 32819, United States
  • Research Site
    Pensacola, Florida 32503, United States
  • Research Site
    St. Petersburg, Florida 33707, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Rincon, Georgia 31326, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    O'Fallon, Illinois 62269, United States
  • Research Site
    Peoria, Illinois 61636, United States
  • Research Site
    Michigan City, Indiana 46360, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Georgetown, Kentucky 40324, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Omaha, Nebraska 68124, United States
  • Research Site
    Toms River, New Jersey 08755, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Burlington, North Carolina 27215, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Elizabeth City, North Carolina 27909, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Mooresville, North Carolina 28117, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Oklahoma City, Oklahoma 73106, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Smithfield, Pennsylvania 15478, United States
  • Research Site
    Mt. Pleasant, South Carolina 29464, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Franklin, Tennessee 37067, United States
  • Research Site
    Hendersonville, Tennessee 37075, United States
  • Research Site
    Johnson City, Tennessee 37601, United States
  • Research Site
    Amarillo, Texas 79106, United States
  • Research Site
    Amarillo, Texas 79124, United States
  • Research Site
    Cypress, Texas 77429, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77079, United States
  • Research Site
    Kerrville, Texas 78028, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Tomball, Texas 77375, United States
  • Research Site
    Salt Lake City, Utah 84102, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Williamsburg, Virginia 23188, United States
  • Research Site
    Everett, Washington 98208, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Morgantown, West Virginia 26505, United States
  • Research Site
    Cudahy, Wisconsin 53110, United States
  • Research Site
    Buenos Aires, S2000PBJ, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Ciudad Autónoma de Buenos Aire, C1440BRR, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1425, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Florida, B1602DQD, Argentina
  • Research Site
    Mar del Plata, B7600GWV, Argentina
  • Research Site
    Mendoza, M5500CCG, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Caringbah, 2229, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Southport, 4215, Australia
  • Research Site
    Spearwood, 6163, Australia

Showing the first 100 of 342 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jul 2025, 71 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 109 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 71 months is above that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Aug 12, 2019
StartActual
Aug 26, 2019
Primary completionActual
Jul 28, 2025
CompletionActual
Jul 28, 2025
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Sites
1 site added, 2 sites removed
Show site
  • Research Site · Chicoutimi, Canada
Show 2 removed
  • Research Site · Chicoutimi, Canada
  • Research Site · Lodz, Poland
Nov 20, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedAnnualized rateRate of moderateModerate or severeSevere COPD exacerbationsExacerbations of Participants With >=3 Exacerbations in the Previous Year.Time frame: Over first 56 weeks → up to Week 56
  • AddedAnnualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
Nov 20, 2026
Documents
Secondary outcomes
3 edited, 15 added, 12 removed, 2 more
What changed in the outcomes
  • EditedAnnualized rateRate of COPD exacerbations that are associated withExacerbations That Are Associated With an emergency roomEmergency Room/emergency department visitEmergency Department Visit or a hospitalizationHospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous YearTime frame: Minimum of 1 year and an average of 2 years → Through study completion, a maximum of 296 weeks
  • EditedKey Secondary Endpoint: Change from baselineFrom Baseline in SGRQ totalTotal and domain scoresDomain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to 56 weeks → up to Week 56
  • EditedAll -cause and respiratoryRespiratory-related mortality rateMortality of Participants With >=3 Exacerbations in the Previous Year.Time frame: Minimum of 1 year and an average of 2 years → Through study completion, a maximum of 296 weeks.
  • AddedKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
  • AddedKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
  • AddedKey Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
  • AddedKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to Week 56
  • AddedKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
  • AddedAnnualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
  • AddedTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to Week 56
  • AddedTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
  • AddedTime From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous YearTime frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
  • AddedTime From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous YearTime frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
  • AddedChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
  • AddedChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.Time frame: up to Week 56
  • AddedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
  • AddedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.Time frame: up to Week 56
  • AddedAll-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.Time frame: Through study completion, a maximum of 296 weeks.
  • RemovedAnnualized rate of severe COPD exacerbationsTime frame: Minimum of 1 year and an average of 2 years
  • RemovedTime to first COPD exacerbationTime frame: During first 56 weeks
  • RemovedChange from baseline in E-RS:COPD total and domain scoresTime frame: up to 56 weeks
  • RemovedChange from baseline in pre-dose/pre-bronchodilator FEV1Time frame: up to 56 weeks
  • RemovedAnnual rate of hospitalizations due to COPDTime frame: Minimum of 1 year and an average of 2 years
  • RemovedSerum benralizumab concentration as a measure of pharmacokineticsTime frame: up to 56 weeks
  • RemovedAnti-drug antibodies (ADA) as a measure of immunogenicityTime frame: up to 56 weeks
  • RemovedChange from baseline in CAT total scoreTime frame: up to 56 weeks
  • RemovedLength of hospital stayTime frame: Minimum of 1 year and an average of 2 years
  • RemovedICU (Intensive Care Unit) daysTime frame: Minimum of 1 year and an average of 2 years
  • RemovedAnnual rate of hospitalizations and emergency department visits combinedTime frame: Minimum of 1 year and an average of 2 years
  • RemovedAnnual rate of unscheduled outpatient visits including unscheduled visits to study sitesTime frame: Minimum of 1 year and an average of 2 years
  • …and 2 more, on the record history on ClinicalTrials.gov ↗
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    1 site added, 2 sites removed
    Show site
    • Research Site · Chicoutimi, Canada
    Show 2 removed
    • Research Site · Chicoutimi, Canada
    • Research Site · Lodz, Poland
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedAnnualized rateRate of moderateModerate or severeSevere COPD exacerbationsExacerbations of Participants With >=3 Exacerbations in the Previous Year.Time frame: Over first 56 weeks → up to Week 56
    • AddedAnnualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
    Secondary outcomes 3 edited, 15 added, 12 removed, 2 more
    What changed in the outcomes
    • EditedAnnualized rateRate of COPD exacerbations that are associated withExacerbations That Are Associated With an emergency roomEmergency Room/emergency department visitEmergency Department Visit or a hospitalizationHospitalization Due to COPD of Participants With >=3 Exacerbations in the Previous YearTime frame: Minimum of 1 year and an average of 2 years → Through study completion, a maximum of 296 weeks
    • EditedKey Secondary Endpoint: Change from baselineFrom Baseline in SGRQ totalTotal and domain scoresDomain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to 56 weeks → up to Week 56
    • EditedAll -cause and respiratoryRespiratory-related mortality rateMortality of Participants With >=3 Exacerbations in the Previous Year.Time frame: Minimum of 1 year and an average of 2 years → Through study completion, a maximum of 296 weeks.
    • AddedKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
    • AddedKey Secondary Endpoint: Annualized Rate of Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
    • AddedKey Secondary Endpoint: Change From Baseline in SGRQ Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
    • AddedKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to Week 56
    • AddedKey Secondary Endpoint: Change From Baseline in Pre-bronchodilator FEV1 (mL) at Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
    • AddedAnnualized Rate of COPD Exacerbations That Are Associated With an Emergency Room/Emergency Department Visit or a Hospitalization Due to COPD of Participants With >=2 Exacerbations in the Previous YearTime frame: Through study completion, a maximum of 296 weeks
    • AddedTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=3 Exacerbations in the Previous YearTime frame: up to Week 56
    • AddedTime From Randomization to the First Moderate or Severe COPD Exacerbation up to Week 56 of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
    • AddedTime From Randomization to the First Severe COPD Exacerbation of Participants With >=3 Exacerbations in the Previous YearTime frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
    • AddedTime From Randomization to the First Severe COPD Exacerbation of Participants With >=2 Exacerbations in the Previous YearTime frame: From date of randomization until the date of first severe COPD exacerbation, assessed through study completion with a maximum of 296 weeks.
    • AddedChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
    • AddedChange From Baseline in COPD Assessment Tool (CAT) Total Score up to Week 56 of Participants With >=2 Exacerbations in the Previous Year.Time frame: up to Week 56
    • AddedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
    • AddedChange From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total and Domain Scores at Week 56 of Participants With >=2 Exacerbations in the Previous Year.Time frame: up to Week 56
    • AddedAll-cause and Respiratory-related Mortality of Participants With >=2 Exacerbations in the Previous Year.Time frame: Through study completion, a maximum of 296 weeks.
    • RemovedAnnualized rate of severe COPD exacerbationsTime frame: Minimum of 1 year and an average of 2 years
    • RemovedTime to first COPD exacerbationTime frame: During first 56 weeks
    • RemovedChange from baseline in E-RS:COPD total and domain scoresTime frame: up to 56 weeks
    • RemovedChange from baseline in pre-dose/pre-bronchodilator FEV1Time frame: up to 56 weeks
    • RemovedAnnual rate of hospitalizations due to COPDTime frame: Minimum of 1 year and an average of 2 years
    • RemovedSerum benralizumab concentration as a measure of pharmacokineticsTime frame: up to 56 weeks
    • RemovedAnti-drug antibodies (ADA) as a measure of immunogenicityTime frame: up to 56 weeks
    • RemovedChange from baseline in CAT total scoreTime frame: up to 56 weeks
    • RemovedLength of hospital stayTime frame: Minimum of 1 year and an average of 2 years
    • RemovedICU (Intensive Care Unit) daysTime frame: Minimum of 1 year and an average of 2 years
    • RemovedAnnual rate of hospitalizations and emergency department visits combinedTime frame: Minimum of 1 year and an average of 2 years
    • RemovedAnnual rate of unscheduled outpatient visits including unscheduled visits to study sitesTime frame: Minimum of 1 year and an average of 2 years
    • …and 2 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04053634
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 12, 2019
Start date
Aug 26, 2019
Primary completion
Jul 28, 2025
Completion
Jul 28, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Gerard Criner, MD
principal investigator · Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion